Stress Urinary Incontinence
Conditions
Brief summary
To assess the impact of Duloxetine and Imipramine on therapeutic efficacy, psychological distress, sexual function, bladder wall structure and blood flow in women
Detailed description
To assess the impact of Duloxetine and Imipramine on therapeutic efficacy, psychological distress, sexual function, bladder wall structure and blood flow in women
Interventions
DRUGDuloxetine
Duloxetine 30 mg qd
DRUGImipramine
Imipramine 25mg qd
Sponsors
Far Eastern Memorial Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- Stress urinary incontinence
Exclusion criteria
1. Take monoamine oxidase 2. Myocardial infarction critical,cardiovascular insufficiency (such as room blocking, arrhythmia, blood-soaked heart failure, myocardial infarction, stroke and excessive heartbeat). 3. Allergy to duloxetine or imipramine 4. Uncontrolled angular glaucoma patients 5. Pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the score of International Consultation on Incontinence Questionnaire-Urinary Incontinence | 8 weeks | Between-group difference in the score of International Consultation on Incontinence Questionnaire-Urinary Incontinence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the score of Urgency Severity Scale | 8 weeks | Between-group difference in the score of Urgency Severity Scale |
Other
| Measure | Time frame | Description |
|---|---|---|
| the score of Overactive Bladder Symptom Score | 8 weeks | Between-group difference in the score of Overactive Bladder Symptom Score |
| the score of King's health questionnaires | 8 weeks | Between-group difference in the score of King's health questionnaires |
| Blood flow index of the bladder | 8 weeks | Between-group difference in the changes of blood flow index of the bladder |
| the score of Female sexual function index | 8 weeks | Between-group difference in the score of Female sexual function index |
| the score of Brief symptom rating scale | 8 weeks | Between-group difference in the score of Brief symptom rating scale |
| Bladder wall thickness | 8 weeks | Between-group difference in the changes of Bladder wall thickness |
Countries
Taiwan
Outcome results
None listed